This review article examines the use of growth factors and the stable gastric pentadecapeptide BPC 157 for treating injuries to tendons, ligaments, muscles, and their associated junctions with bone. The authors synthesize evidence from multiple research domains showing that BPC 157 exhibits angiogenic, anti-inflammatory, and tissue-regenerative properties in preclinical models of musculoskeletal injury. The evidence base includes human clinical studies, animal models, and in vitro research, though this is a literature review rather than original research.